Cara Therapeutics
CARA
#5040
Rank
$0.61 B
Marketcap
$11.51
Share price
-1.03%
Change (1 day)
-16.90%
Change (1 year)

P/E ratio for Cara Therapeutics (CARA)

P/E ratio as of August 2022 (TTM): -6.47

According to Cara Therapeutics 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -6.46629. At the end of 2021 the company had a P/E ratio of -7.04.

P/E ratio history for Cara Therapeutics from 2014 to 2022

PE ratio at the end of each year

Year P/E ratio Change
2021-7.04
2019-6.472.52%
2018-6.31-1.52%
2017-6.4144.86%
2016-4.42-73.76%
2015-16.943.74%
2014-11.7

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.